Krishna Kattel1, Ruby Evande2, Chalet Tan3, Goutam Mondal1, Jean L Grem2, Ram I Mahato1. 1. Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA. 2. Department of Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA. 3. Department of Pharmaceutical Sciences, Mercer University, Atlanta, GA 30341, USA.
Abstract
AIM: This study evaluated the influence of CYP2C19 polymorphisms on the pharmacokinetics of nelfinavir and its metabolite M8 in patients with pancreatic cancer. METHODS: Nelfinavir was administered orally to patients for over 10 days. The plasma concentrations of nelfinavir and M8 were measured by HPLC. The genotypes of CYP2C19*1, CYP2C19*2 and CYP2C19*3 were determined by the polymerase chain reaction-restriction fragment length polymorphism method. RESULTS: Pharmacokinetic profiles of nelfinavir and M8 were characterized by wide interindividual variability. The mean Cmax of nelfinavir in CYP2C19*1/*1 patients was 3.89 ± 0.40 (n = 3) and 5.12 ± 0.41 (n = 30) µg ml(-1) , while that of CYP2C19*1/*2 patients was 3.60 (n = 1) and 6.14 ± 0.31 (n = 5) µg ml(-1) at the doses of 625 and 1250 mg nelfinavir twice daily, respectively. For the M8 metabolite, the mean Cmax of CYP2C19*1/*1 patients was 1.06 ± 0.06 (n = 3) and 1.58 ± 0.27 (n = 30) µg ml(-1) , while those of CYP2C19*1/*2 patients were 1.01 (n = 1) and 1.23 ± 0.15 (n = 5) µg ml(-1) at the doses of 625 and 1250 mg nelfinavir twice daily, respectively. The area under the plasma concentration-time curve (AUC(0,12 h)) values of nelfinavir for CYP2C19*1/*1 patients were 28.90 ± 1.27 and 38.90 ± 4.99 µg ml(-1) ·h and for CYP2C19*1/*2 patients, AUC(0,12 h) was 28.20 (n = 1) and 40.22 ± 3.17 (n = 5) µg ml(-1) ·h at the doses of 625 and 1250 mg nelfinavir twice daily, respectively. The Cmax of nelfinavir was significantly higher (P <0.05) in CYP2C19*1/*2 patients but there was no statistical difference in AUC(0,12 h). CONCLUSION: CYP2C19*1/*2 genotype modestly affected the pharmacokinetic profiles of nelfinavir and M8 in patients with locally advanced pancreatic cancer.
AIM: This study evaluated the influence of CYP2C19 polymorphisms on the pharmacokinetics of nelfinavir and its metabolite M8 in patients with pancreatic cancer. METHODS:Nelfinavir was administered orally to patients for over 10 days. The plasma concentrations of nelfinavir and M8 were measured by HPLC. The genotypes of CYP2C19*1, CYP2C19*2 and CYP2C19*3 were determined by the polymerase chain reaction-restriction fragment length polymorphism method. RESULTS: Pharmacokinetic profiles of nelfinavir and M8 were characterized by wide interindividual variability. The mean Cmax of nelfinavir in CYP2C19*1/*1 patients was 3.89 ± 0.40 (n = 3) and 5.12 ± 0.41 (n = 30) µg ml(-1) , while that of CYP2C19*1/*2 patients was 3.60 (n = 1) and 6.14 ± 0.31 (n = 5) µg ml(-1) at the doses of 625 and 1250 mg nelfinavir twice daily, respectively. For the M8 metabolite, the mean Cmax of CYP2C19*1/*1 patients was 1.06 ± 0.06 (n = 3) and 1.58 ± 0.27 (n = 30) µg ml(-1) , while those of CYP2C19*1/*2 patients were 1.01 (n = 1) and 1.23 ± 0.15 (n = 5) µg ml(-1) at the doses of 625 and 1250 mg nelfinavir twice daily, respectively. The area under the plasma concentration-time curve (AUC(0,12 h)) values of nelfinavir for CYP2C19*1/*1 patients were 28.90 ± 1.27 and 38.90 ± 4.99 µg ml(-1) ·h and for CYP2C19*1/*2 patients, AUC(0,12 h) was 28.20 (n = 1) and 40.22 ± 3.17 (n = 5) µg ml(-1) ·h at the doses of 625 and 1250 mg nelfinavir twice daily, respectively. The Cmax of nelfinavir was significantly higher (P <0.05) in CYP2C19*1/*2 patients but there was no statistical difference in AUC(0,12 h). CONCLUSION:CYP2C19*1/*2 genotype modestly affected the pharmacokinetic profiles of nelfinavir and M8 in patients with locally advanced pancreatic cancer.
Authors: A K Gupta; V J Bakanauskas; G J Cerniglia; Y Cheng; E J Bernhard; R J Muschel; W G McKenna Journal: Cancer Res Date: 2001-05-15 Impact factor: 12.701
Authors: Y Khaliq; K Gallicano; I Seguin; K Fyke; G Carignan; D Bulman; A Badley; D W Cameron Journal: Br J Clin Pharmacol Date: 2000-08 Impact factor: 4.335
Authors: Jennifer J Kiser; Richard M Rutstein; Pearl Samson; Bobbie Graham; Grace Aldrovandi; Lynne M Mofenson; Elizabeth Smith; Steven Schnittman; Terry Fenton; Richard C Brundage; Courtney V Fletcher Journal: AIDS Date: 2011-07-31 Impact factor: 4.177
Authors: J H Klinkenbijl; J Jeekel; T Sahmoud; R van Pel; M L Couvreur; C H Veenhof; J P Arnaud; D G Gonzalez; L T de Wit; A Hennipman; J Wils Journal: Ann Surg Date: 1999-12 Impact factor: 12.969
Authors: Anjali K Gupta; George J Cerniglia; Rosemarie Mick; W Gillies McKenna; Ruth J Muschel Journal: Cancer Res Date: 2005-09-15 Impact factor: 12.701
Authors: Jeroen Buijsen; Guido Lammering; Rob L H Jansen; Geerard L Beets; Jaap Wals; Meindert Sosef; Marien O Den Boer; Jeroen Leijtens; Robert G Riedl; Jan Theys; Philippe Lambin Journal: Radiother Oncol Date: 2013-05-03 Impact factor: 6.280
Authors: Nabendu Pore; Anjali K Gupta; George J Cerniglia; Zibin Jiang; Eric J Bernhard; Sydney M Evans; Cameron J Koch; Stephen M Hahn; Amit Maity Journal: Cancer Res Date: 2006-09-15 Impact factor: 12.701
Authors: Zibin Jiang; Nabendu Pore; George J Cerniglia; Rosemarie Mick; Maria-Magdelena Georgescu; Eric J Bernhard; Stephen M Hahn; Anjali K Gupta; Amit Maity Journal: Cancer Res Date: 2007-05-01 Impact factor: 12.701
Authors: Emily J Cox; Neha Maharao; Gabriela Patilea-Vrana; Jashvant D Unadkat; Allan E Rettie; Jeannine S McCune; Mary F Paine Journal: Pharmacol Ther Date: 2019-05-07 Impact factor: 12.310
Authors: Mahbuba R Subeha; Alicia A Goyeneche; Prisca Bustamante; Michael A Lisio; Julia V Burnier; Carlos M Telleria Journal: Cancers (Basel) Date: 2021-12-26 Impact factor: 6.639